International Journal of Advanced Research in Medicinal Chemistry
Volume 6, Issue 1 - 2024, Pg. No. 21-25
Peer Reviewed Journal

Review Article

Cholinergic Drugs: Risks, Symptoms, and Management Strategies

Prahlad Kumar[1], Kanika Srivastava[2]

[1,2]Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela.

I N F O

Corresponding Author:
Prahlad Kumar, Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela.
E-mail Id:
prahladk4656@gmail.com
How to cite this article:
Kumar P, Srivastava K. Cholinergic Drugs: Risks, Symptoms, and Management Strategies. J Adv Res in medc che 2024; 6(1): 21-25.

Date of Submission: 2024-04-19
Date of Acceptance: 2024-05-20

A B S T R A C T

Cholinergic medications primarily affect the main neurotransmitter in the parasympathetic nervous system (PNS), acetylcholine. They are categorized into two main types: direct-acting and indirect-acting drugs. Direct-acting cholinergic agonists bind directly to muscarinic receptors, exemplified by choline esters (such as acetylcholine, methacholine, carbachol, bethanechol, tacrine) and alkaloids (including muscarine, pilocarpine, and cevimeline). Indirect-acting cholinergic agents increase acetylcholine availability at cholinergic receptors. Reversible agents (such as physostigmine, neostigmine, pyridostigmine, edrophonium, rivastigmine, donepezil, and galantamine) and irreversible agents (like echothiophate, parathion, Malathion, diazinon, tabun, sarin, soman, carbaryl, and propoxur) are included in this category. Their use can lead to adverse effects across organs controlled by the parasympathetic nervous system, highlighting the limitations of cholinergic agonists despite their therapeutic benefits.

Keywords: Cholinergic Drugs, Pns, Neurotransmitters, Sign & Symptoms

Introduction

Cholinergic medications represent a pivotal class of therapeutic agents that exert their effects by modulating cholinergic receptors, essential for the regulation of numerous physiological processes. These medications, including acetylcholinesterase inhibitors and muscarinic agonists, are widely employed in the treatment of diverse medical conditions such as Alzheimer's disease, myasthenia gravis, and glaucoma. While invaluable in clinical practice, their use carries inherent risks of toxicity, ranging from mild symptoms such as gastrointestinal disturbances to severe manifestations like respiratory failure and cardiovascular collapse. Effective management of cholinergic toxicity demands a nuanced understanding of their pharmacological actions, toxicity profiles, and targeted therapeutic interventions. This review explores the pharmacology, mechanisms of toxicity, clinical manifestations, diagnostic approaches, and evidence-based management strategies pertinent to cholinergic medication-associated toxicity, aiming to enhance clinician preparedness and optimize patient outcomes in diverse clinical settings.[1,2]

Pharmacology of Cholinergic Medications

Cholinergic medications constitute a class of drugs that exert their effects by influencing the cholinergic system, particularly through interaction with acetylcholine receptors. These medications are crucial in the management of various medical conditions, including neurodegenerative diseases, neuromuscular disorders, and ophthalmic conditions, among others. Understanding their pharmacology is essential for optimizing therapeutic outcomes while mitigating potential adverse effects associated with their use.

Mechanism of Action

Cholinergic medications primarily act by either directly stimulating cholinergic receptors or by indirectly increasing the availability of acetylcholine (ACh) in the synaptic cleft. Direct-acting cholinergic agonists bind directly to and activate muscarinic or nicotinic receptors. Muscarinic receptors are G protein-coupled receptors found in various tissues, including smooth muscle, cardiac muscle, and glands, while nicotinic receptors are ligand-gated ion channels present in skeletal muscle and autonomic ganglia.[3]

Types of Cholinergic Medications

Direct-Acting Cholinergic Agonists

Direct-acting cholinergic agonists mimic the action of acetylcholine by binding directly to muscarinic receptors (M1 to M5) or nicotinic receptors (N1 to N2). Examples include:

- **Muscarinic Receptor Agonists:** Drugs like pilocarpine and cevimeline primarily target muscarinic receptors in tissues such as the eye (for treating glaucoma) and salivary glands (for stimulating saliva production).[4]
- **Nicotinic Receptor Agonists:** Nicotine is an example that acts on nicotinic receptors in the autonomic ganglia and skeletal muscle.

Indirect-Acting Cholinergic Agonists (Cholinesterase Inhibitors):

Indirect-acting cholinergic agonists inhibit the enzyme acetylcholinesterase (AChE), which normally breaks down acetylcholine. By inhibiting AChE, these drugs increase the concentration of acetylcholine at cholinergic synapses, enhancing cholinergic transmission. They are further classified into:

- **Reversible Inhibitors:** Examples include physostigmine, neostigmine, pyridostigmine, and rivastigmine. These drugs bind to acetylcholinesterase temporarily and are used in conditions such as myasthenia gravis (to improve neuromuscular transmission) and Alzheimer's disease (to enhance cognitive function).
- **Irreversible Inhibitors:** Agents like organophosphates (e.g., echothiophate) irreversibly bind to and inhibit acetylcholinesterase, leading to prolonged elevation of acetylcholine levels. They are highly toxic and used primarily as insecticides or chemical warfare agents.[5]

Toxicity of Cholinergic Medications

Cholinergic medications, while beneficial in therapeutic contexts, pose significant risks of toxicity due to their ability to excessively stimulate cholinergic receptors throughout the body. Understanding the manifestations, mechanisms, and management of cholinergic toxicity is crucial for healthcare providers to ensure timely intervention and mitigate potential adverse outcomes. Cholinergic drugs can induce undesirable effects through stimulation of muscarinic and/or nicotinic receptors. Acetylcholine, acting via M2 receptors, hyperpolarizes SA nodal cells in the heart, potentially leading to bradycardia or cardiac arrest. Slowed conduction and complete AV block can occur at the AV node and Purkinje fibers. Variability in vagal innervation of atrial fibers may predispose individuals to atrial fibrillation or flutter. Activation of M3 receptors on blood vessels causes dilation, resulting in hypotension and flushing. Cholinergic nerve stimulation induces smooth muscle contraction in the penis, leading to erection. Smooth muscle contraction mediated through M3 receptors causes abdominal cramps and bowel evacuation by increasing tone and peristalsis in the gastrointestinal tract and relaxing sphincters. Bronchial muscle contraction precipitates bronchial asthma attacks.[6] Enhanced secretion from glands via M3 and M2 receptors results in salivation, lacrimation, sweating, and secretion in the tracheobronchial and gastric systems. Pilocarpine eye drops cause iris contraction (miosis) and accommodation spasm. Acetylcholine, unable to cross the blood-brain barrier, has no intravenous effects; however, cholinergic drugs can enter the brain, leading to initial stimulation followed by depression. Muscarinic receptors primarily stimulate ganglia in the presence of anti-cholinesterase drugs. Acetylcholine release from nerve impulses in skeletal muscles treated with anticholinesterases may cause trembling and fasciculations due to rhythmic firing. Higher doses of anticholinesterase drugs block impulse transmission at neuromuscular junctions, causing muscle weakness or paralysis. Organophosphates and physostigmine exhibit pronounced muscarinic and central nervous system effects, with less impact on skeletal muscles but greater ganglionic stimulation. Neostigmine and similar agents have a clearer effect on skeletal muscles and strong ganglionic stimulation, with less pronounced muscarinic effects. Inappropriate or excessive medication doses or accidental exposure to pesticides like Malathion or parathion are common causes of cholinergic crises.[7,8]

Mechanisms of Toxicity

Cholinergic toxicity primarily results from an overactivation of cholinergic receptors, predominantly muscarinic receptors in various organs and nicotinic receptors in skeletal muscle and autonomic ganglia. This excessive stimulation leads to a cascade of physiological responses that can manifest as a spectrum of symptoms ranging from mild to severe.

Clinical Manifestations

The clinical presentation of cholinergic toxicity varies widely depending on the extent of receptor stimulation and individual susceptibility. Common symptoms include:

Effects of Cholinergic Medications on the Human Body

Cholinergic medications exert their effects by modulating the cholinergic system, influencing various physiological processes through interactions with acetylcholine receptors. These medications are used therapeutically in the treatment of several medical conditions, but they also carry risks of adverse effects related to excessive cholinergic stimulation.[7-9]

- **Cardiovascular Effects:** Cholinergic medications, through their action on muscarinic receptors, can affect cardiovascular function. Activation of M2 receptors in the heart's SA node leads to hyperpolarization of nodal cells, potentially causing bradycardia or even cardiac arrest. Slowed conduction and complete AV block may occur at the AV node and Purkinje fibers. In individuals with non-uniform vagal innervation of atrial fibers, there may be a predisposition to atrial fibrillation or flutter. These effects underscore the importance of careful dosing and monitoring in patients with cardiac conditions.
- **Vascular Effects:** M3 receptors on blood vessels mediate vasodilation when stimulated by cholinergic drugs. This can lead to hypotension and flushing, which are particularly notable during intravenous administration or with high doses of medications.
- **Genitourinary Effects:** Cholinergic stimulation of erectile tissue through cholinergic nerves induces penile erection. This effect is mediated by the activation of muscarinic receptors in smooth muscle cells of the corpus cavernosum.[10]
- **Gastrointestinal Effects:** Cholinergic medications enhance gastrointestinal motility and secretions through stimulation of muscarinic receptors. Increased tone and peristalsis in the gastrointestinal tract can lead to abdominal cramps and diarrhea. Relaxation of sphincters facilitates bowel evacuation.
- **Respiratory Effects:** Bronchial smooth muscle contraction, precipitated by cholinergic medications acting on M3 receptors, may exacerbate bronchial asthma or lead to bronchoconstriction in susceptible individuals.
- **Ocular Effects:** Pilocarpine, a direct-acting cholinergic agonist, causes contraction of the iris (miosis) and spasm of accommodation when administered as eye drops. This effect is beneficial in treating conditions like glaucoma by facilitating the drainage of intraocular fluid.
- **Secretory Effects:** Stimulation of M3 and M2 receptors enhances secretions from glands throughout the body, resulting in increased salivation, lacrimation (tear production), sweating, and secretion in the respiratory and gastrointestinal tracts. This can be clinically relevant in conditions requiring enhanced mucosal secretions for diagnostic or therapeutic purposes.[11, 12]
- **Central Nervous System Effects:** While acetylcholine itself does not cross the blood-brain barrier, cholinergic medications can have indirect effects on the central nervous system (CNS). They may enter the brain, leading to a complex pattern of initial stimulation followed by depression. This CNS penetration can be relevant in understanding the therapeutic and adverse effects of cholinergic drugs in neurological conditions.
- **Musculoskeletal Effects:** In the skeletal muscles, cholinergic medications can enhance neuromuscular transmission by inhibiting acetylcholinesterase, which breaks down acetylcholine. This effect is utilized in the treatment of myasthenia gravis and other neuromuscular disorders but can also lead to adverse effects such as trembling, fasciculations (muscle twitches), and in severe cases, weakness or paralysis due to prolonged neuromuscular blockade.
- **Toxicity and Adverse Effects:** Excessive cholinergic stimulation, whether due to overdose, inappropriate dosing, or inadvertent exposure to cholinergic agents (such as pesticides), can lead to cholinergic crisis. Symptoms may include severe cardiovascular effects (bradycardia, hypotension), respiratory distress (bronchoconstriction), gastrointestinal disturbances (nausea, vomiting, diarrhea), and neurological manifestations (seizures, confusion). Management involves supportive care, antidotal therapy with atropine or pralidoxime, and in severe cases, intensive monitoring and respiratory support.[13]

Factors Influencing Toxicity

Several factors contribute to the severity and onset of cholinergic toxicity:

Dosage and Route of Administration: Higher doses or parenteral administration (e.g., intravenous) increase the risk of toxicity.

Individual Sensitivity: Variation in cholinergic receptor density and sensitivity among individuals.

Drug Interactions: Concurrent use of other medications that affect cholinergic pathways (e.g., anticholinergics, cholinesterase inhibitors).

Underlying Health Conditions: Pre-existing cardiovascular disease, respiratory disorders, or impaired hepatic or renal function can exacerbate toxicity.[14]

Administration

In various formulations, cholinergic medications are available. Such as, pilocarpine and physostigmine when used

as a miotic agent, the administration is via ophthalmic eye drops. But pyridostigmine dosing is oral for the treatment of myasthenia gravis; sometimes medication is administered parenterally to patients who cannot take it orally. For example, organophosphates get absorbed from all sites, counting intact skin and lungs, while in Alzheimer diseases; rivastigmine, donepezil, and galantamine are administered orally. In individuals with spinal cord injury, transdermal administration of neostigmine by iontophoresis seems to be operative to induce bowel evacuation. Some other anti-cholinesterase medications employed for curing numerous other situations are usually parenterally administered.[15]

Monitoring

Proper testing is proposed to recognize overexposure before the incidence of clinical sickness. Agricultural workers who handle organophosphates for a prolonged period should have medical monitoring time to time. Both RBC cholinesterase and serum must be determined. According to a programme baseline blood samples may be achieved and evaluated with the samples on a schedule 30-day basis

Evaluate the employee's work practices to categorize and correct possible sources of pesticide toxicity. If an employee's RBC or serum cholinesterase value fall more than 20% below the baseline.

Treatment / Management

Assessment and management of every victim must begin with ABC's (airway, breathing, circulation, disability, and exposure). Regular airway and circulatory support is compulsory with two exemptions. Succinylcholine must not be applied during intubation because the lack of acetyl cholinesterase caused by the poisoning will cause extended paralysis. All clothes should be removed and disposed. Strong refinement is compulsory. The eyes and skin should be cleansed to prevent incorporation of the toxic compound. Healthcare staffs have to wear protective devices to avoid inhalation and dermal contact to the agent.[4,5]

Treatment should include IV administration of atropine and pralidoxime in suspicion; usually pralidoxime transiently aggravate the symptoms therefore Atropine is administrate first. Atropine by antagonizing the muscarinic receptor's effort of excessive acetylcholine for example bronchorrhea, bradycardia, salivation, and bronchoconstriction. Thus it acts as a direct antidote physiologically. Atropine can help decrease the activity of centrally acting excess acetylcholine since it can cross the blood-brain barrier. Until the pulmonary symptoms improve, the initial dose of IV atropine is 0.05 mk/kg in children and 2 to 5 mg in adults every 5 minutes. To ease bronchorrhea and bronchospasm atropine must be titrated; as treatment may take several days this may need large doses of atropine. For extra atropine supply the hospital pharmacy should receive a prior notice for better treatment.[7]

Oximes such as pralidoxime are administrated as it is having three actions that demonstrate better result in acute cholinergic toxicity. Besides atropine does not bind to nicotinic receptors, does not cure neuromuscular dysfunction that's why it is not employed. Pralidoxime reactivates acetyl cholinesterase, supplies endogenous anticholinergic results, and detoxifies free organophosphates. When there are symptoms of muscle weakness, particularly if the weakness is going on within the respiratory system oximes are used as it work on the nicotinic neuromuscular junction, and therefore most patients with organophosphate poisoning necessitate treatment with an oxime; this is due to the likelihood of delayed toxicity and the variability of responses to Oximes. The FDA recommended dosage of pralidoxime for organophosphate poisoning is 1 to 2 g infusion over 30 minutes which can be recurring in one hour if there is persistence of muscle weakness. A continuous infusion may also be compulsory after the bolus dose. Obtain a toxicology centre consultation if possible in the locality. Victim should receive treatment with benzodiazepines if there persist any episode of seizures, anti-epileptics drugs must be avoided. Since in the organophosphate toxicity diazepam decreases prophylactic neuropathological damages.[9-11]

Conclusion

Cholinergic drugs, while indispensable in the treatment of various medical conditions, present significant risks if not managed properly. The balance between therapeutic efficacy and the potential for toxicity necessitates a thorough understanding of the factors influencing adverse effects. Recognizing the symptoms of cholinergic toxicity—ranging from cardiovascular and respiratory complications to gastrointestinal and neurological disturbances—is crucial for timely intervention. Effective management strategies, including supportive care, decontamination, and the use of antidotes like atropine and pralidoxime, are vital for mitigating these risks. By maintaining vigilance and adhering to established protocols, healthcare providers can optimize patient outcomes and harness the therapeutic benefits of cholinergic drugs while minimizing their potential harms.

References

1. Ehret MJ, Chamberlin KW. Current practices in the treatment of alzheimer disease: where is the evidence after the phase III trials? Clin Ther. 2015; 37(8): 1604-16.
2. Pepeu G, Giovannini MG. Cholinesterase inhibitors and beyond. Curr Alzheimer Res. 2009; 6(2): 86-96.
3. Korsten MA, Lyons BL, Radulovic M, et al. Delivery of neostigmine and glycopyrrolate by iontophoresis: a nonrandomized study in individuals with spinal cord

injury. Spinal Cord. 2018; 56(3): 212-7.
4. Ohbe H, Jo T, Matsui H, et al. Cholinergic Crisis Caused by Cholinesterase Inhibitors: a Retrospective Nationwide Database Study. J Med Toxicol. 2018; 14(3): 237-41.
5. Adeyinka A, Kondamudi NP. StatPearls Publishing; Treasure Island (FL): Mar 24, 2019. Cholinergic Crisis.
6. Houzé P, Berthin T, Raphalen JH, et al. High dose of pralidoxime reverses paraoxon-induced respiratory toxicity in mice. Turk J Anaesthesiol Reanim. 2018; 46(2): 131-8.
7. Wiercinski A, Jackson JP. StatPearls Publishing; Treasure Island (FL): Jun 3, 2019. Nerve Agents.
8. Vanova N, Pejchal J, Herman D, et al. Oxidative stress in organophosphate poisoning: role of standard antidotal therapy. J Appl Toxicol. 2018; 38(8): 1058-70.
9. Antonijevic E, Kotur-Stevuljevic J, Musilek K, et al. Effect of six oximes on acutely anticholinesterase inhibitor-induced oxidative stress in rat plasma and brain. Arch Toxicol. 2018; 92(2): 745-57.
10. Malinak D, Nepovimova E, Jun D, et al. Novel group of AChE reactivators-synthesis, in vitro reactivation and molecular docking study. Molecules. 2018; 23(9).
11. Arsura EL, Brunner NG, Namba T, et al. Adverse cardiovascular effects of anticholinesterase medications. Am J Med Sci. 1987; 293(1): 18-23.
12. Assis CRD, Linhares AG, Cabrera MP, et al. Erythrocyte acetylcholinesterase as biomarker of pesticide exposure: new and forgotten insights. Environ Sci Pollut Res Int. 2018; 25(19): 18364-76.
13. Haga T. Molecular properties of muscarinic acetylcholine receptors. Proc Jpn Acad Ser B Phys. Biol Sci. 2013; 89(6): 226-56.
14. Gorecki L, Korabecny J, Musilek K, et al. Progress in acetylcholinesterase reactivators and in the treatment of organophosphorus intoxication: a patent review (2006-2016). Expert Opin Ther Pat. 2017; 27(9): 971-85.
15. Jeyaratnam J. Acute pesticide poisoning: a major global health problem. World Health Stat Q. 1990; 43(3): 139-44.